As the leader of Mass General Brigham (MGB) Personalized Medicine, I have developed core laboratories to serve the investigative community at MGH and BWH over the past 10 years. The Translational Genomics Core serves roughly 50 investigators/year and supports over 100 million dollars in NIH grants. We have built the MGB Biobank that has serum, plasma and DNA and is linked to the electronic medical record. The Biobank has over 100,000 consented subjects with samples and 36,000 subjects with genomic data and over 100 investigators receiving free GWAS data and or samples each year. The Biobank supports over 200 million dollars in NIH funded research. Finally, as a result of these resources MGB Personalized Medicine has obtained 73 million dollars in NIH grants for participation in the eMERGE network and the All of Us program. I am currently funded by the NIH and have been for the past 43 years. During this time, I have been PI on over 50 grants and I have made over 300 million dollars for Brigham and Women’s Hospital in indirect costs. I have collaborated with a variety of investigators on cooperative studies such as the Childhood Asthma Management Program (CAMP), SHARE, ABRIDGE, EVE, and TopMed and have served in an administrative capacity with the NHLBI for a variety of genetic epidemiologic programs including the Special Emphasis Panel on the Use of NHLBI Specimens, the Oversight Committee for the Collaborative Study on the Genetics of Asthma, the NHLBI Genotyping Service Study Section, the T-32 training grant study section, over 30 NHLBI workshops, and the oversight panel for the Genotyping and Sequencing Service. I am the Co-Principal Investigator of the only training program in the Clinical and Genetic Epidemiology of Lung Diseases (HL-07427). I have trained a total of 51 investigators; 13 of these trainees have reached the rank of professor, and most remain in academic medicine.